{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:09:12Z","timestamp":1790770152419,"version":"4.1.0"},"reference-count":24,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2016,9,14]],"date-time":"2016-09-14T00:00:00Z","timestamp":1473811200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["30971296"],"award-info":[{"award-number":["30971296"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81170485"],"award-info":[{"award-number":["81170485"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81170488"],"award-info":[{"award-number":["81170488"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81370657"],"award-info":[{"award-number":["81370657"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81470328"],"award-info":[{"award-number":["81470328"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2016,10]]},"abstract":"<jats:p>Tumor microenvironment and host immunity are closely related to outcome in patients with mantle cell lymphoma (<jats:styled-content style=\"fixed-case\">MCL<\/jats:styled-content>). However, few researchers have focused on the prognostic value of peripheral blood lymphocyte subsets counts. The purpose of this study was to investigate the prognostic value of lymphocyte subsets and absolute monocyte counts. Sixty\u2010eight patients were analyzed retrospectively. Absolute <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>4<jats:sup>+<\/jats:sup> T cell counts (<jats:styled-content style=\"fixed-case\">ACD<\/jats:styled-content>4C), <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>8<jats:sup>+<\/jats:sup> T cell counts, nature killer cell counts, and <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>4\/<jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>8 ratios were assessed by peripheral blood flow cytometry and correlated with clinical parameters and long\u2010term outcomes. The median follow\u2010up for all patients was 21 months and the median survival time was 44 months. The overall survival (<jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content>) rate at 1, 3, and 5 years was 80%, 51%, and 41%, respectively. In our cohort, high absolute monocyte count, and low <jats:styled-content style=\"fixed-case\">ACD<\/jats:styled-content>4C and <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>4\/<jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>8 ratio were associated with unfavorable <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content> (<jats:italic>P<\/jats:italic> = 0.029, <jats:italic>P<\/jats:italic> = 0.027, and <jats:italic>P<\/jats:italic> = 0.045, respectively) by univariate analysis. Multivariate analysis indicated that low <jats:styled-content style=\"fixed-case\">ACD<\/jats:styled-content>4C was a significant predictor of unfavorable <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content> (<jats:italic>P<\/jats:italic> = 0.004) independent of the simplified <jats:styled-content style=\"fixed-case\">MCL<\/jats:styled-content> International Prognostic Index (<jats:italic>P<\/jats:italic> = 0.048) in patients treated with or without rituximab (<jats:italic>P<\/jats:italic> = 0.011). Low <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>4<jats:sup>+<\/jats:sup> T cell counts proved to be a significant predictor of unfavorable <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content> in patients with <jats:styled-content style=\"fixed-case\">MCL<\/jats:styled-content>.<\/jats:p>","DOI":"10.1111\/cas.13020","type":"journal-article","created":{"date-parts":[[2016,7,28]],"date-time":"2016-07-28T11:09:11Z","timestamp":1469704151000},"page":"1471-1476","source":"Crossref","is-referenced-by-count":32,"title":["Negative prognostic impact of low absolute <scp>CD<\/scp>4<sup>+<\/sup> T cell counts in peripheral blood in mantle cell lymphoma"],"prefix":"10.1111","volume":"107","author":[{"given":"Xin\u2010Yu","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Hematology The First Affiliated Hospital of Nanjing Medical University Jiangsu Province Hospital Nanjing China"},{"name":"Collaborative Innovation Center for Cancer Personalized Medicine Nanjing Medical University Nanjing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Hematology The First Affiliated Hospital of Nanjing Medical University Jiangsu Province Hospital Nanjing China"},{"name":"Collaborative Innovation Center for Cancer Personalized Medicine Nanjing Medical University Nanjing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua\u2010Yuan","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Hematology The First Affiliated Hospital of Nanjing Medical University Jiangsu Province Hospital Nanjing China"},{"name":"Collaborative Innovation Center for Cancer Personalized Medicine Nanjing Medical University Nanjing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology The First Affiliated Hospital of Nanjing Medical University Jiangsu Province Hospital Nanjing China"},{"name":"Collaborative Innovation Center for Cancer Personalized Medicine Nanjing Medical University Nanjing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology The First Affiliated Hospital of Nanjing Medical University Jiangsu Province Hospital Nanjing China"},{"name":"Collaborative Innovation Center for Cancer Personalized Medicine Nanjing Medical University Nanjing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Hematology The First Affiliated Hospital of Nanjing Medical University Jiangsu Province Hospital Nanjing China"},{"name":"Collaborative Innovation Center for Cancer Personalized Medicine Nanjing Medical University Nanjing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu\u2010Jie","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Hematology The First Affiliated Hospital of Nanjing Medical University Jiangsu Province Hospital Nanjing China"},{"name":"Collaborative Innovation Center for Cancer Personalized Medicine Nanjing Medical University Nanjing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian\u2010Yong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology The First Affiliated Hospital of Nanjing Medical University Jiangsu Province Hospital Nanjing China"},{"name":"Collaborative Innovation Center for Cancer Personalized Medicine Nanjing Medical University Nanjing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Hematology The First Affiliated Hospital of Nanjing Medical University Jiangsu Province Hospital Nanjing China"},{"name":"Collaborative Innovation Center for Cancer Personalized Medicine Nanjing Medical University Nanjing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,9,14]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.5904"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24094"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-095331"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.22123"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2011.09.006"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0889"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-293050"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404517"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-09-3679"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-4-34"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2014.10.001"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23566"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.5045\/br.2014.49.1.15"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22715"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000001631"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-014-3974-1"},{"key":"e_1_2_7_18_1","first-page":"361","article-title":"CD3+, CD4+ & CD8+ tumour infiltrating lymphocytes (TILs) are predictors of favourable survival outcome in infiltrating ductal carcinoma of breast","volume":"140","author":"Rathore AS","year":"2014","journal-title":"Indian J Med Res"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-009-0753-0"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2010.10.002"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.071340"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2106"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12683"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2011.04515.x"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-006-9001-7"}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcas.13020","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cas.13020","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cas.13020","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cas.13020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T01:45:09Z","timestamp":1696297509000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cas.13020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,14]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["10.1111\/cas.13020"],"URL":"https:\/\/doi.org\/10.1111\/cas.13020","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"value":"1347-9032","type":"print"},{"value":"1349-7006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,14]]}}}